Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes

被引:260
作者
Govindarajan, Rangaswamy
Ratnasinghe, Luke
Simmons, Debra L.
Siegel, Eric R.
Midathada, Madhu V.
Kim, Lawrence
Kim, Peter J.
Owens, Randall J.
Lang, Nicholas P.
机构
[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[2] Cent Arkansas Vet Hlth Care Syst, Little Rock, AR USA
关键词
D O I
10.1200/JCO.2006.07.2777
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Peroxisome proliferator-activated receptor gamma (PPAR gamma) mediates cell cycle arrest and adipocyte differentiation; has tumor suppressor activity in liposarcoma, lung, and prostate cancers; and suppresses colonic polyp formation in adenomatous polyposis coli (APC)(min/+) mice. To assess the influence of thiazolidinediones (TZDs), which are PPAR gamma ligands used to treat diabetes mellitus, a retrospective analysis of a database from 10 Veteran Affairs medical centers was conducted. Patients and Methods Data on male patients 40 years and older diagnosed to have diabetes mellitus between 1997 and 2003 were obtained from the Veterans Integrated Services Network 16 (VISN 16) data warehouse. Subsequent diagnoses of colorectal, lung, and prostate cancer and use of TZD, other antidiabetic agents, and insulin were identified. Cox regression with time-dependent covariates was used to estimate the association between TZD use and cancer risk. Relative risks were adjusted for confounders (age, race/ethnicity, body mass index, use of insulin, and other oral antidiabetic agents). Results Of 87,678 individuals, 1,137 had colorectal cancer, 3,246 had prostate cancer, and 1,371 had lung cancer. We observed a 33% reduction in lung cancer risk among TZD users compared with nonusers after adjusting for confounder interactions (relative risk, 0.67; 95% CI, 0.51 to 0.87). The risk reduction for colorectal and prostate cancers did not reach statistical significance. Conclusion TZD use was associated with reduced risk of lung cancer. Further studies are warranted to confirm our findings.
引用
收藏
页码:1476 / 1481
页数:6
相关论文
共 29 条
[1]   Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ -: A novel mechanism for its anti-tumorigenic activity [J].
Baek, SJ ;
Wilson, LC ;
Hsi, LC ;
Eling, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :5845-5853
[2]   Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) [J].
Bren-Mattison, Y ;
Van Putten, V ;
Chan, D ;
Winn, R ;
Geraci, MW ;
Nemenoff, RA .
ONCOGENE, 2005, 24 (08) :1412-1422
[3]   The importance of race and ethnic background in biomedical research and clinical practice [J].
Burchard, EG ;
Ziv, E ;
Coyle, N ;
Gomez, SL ;
Tang, H ;
Karter, AJ ;
Mountain, JL ;
Pérez-Stable, EJ ;
Sheppard, D ;
Risch, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1170-1175
[4]   Peroxisome proliferator-activated receptors: Nuclear control of metabolism [J].
Desvergne, B ;
Wahli, W .
ENDOCRINE REVIEWS, 1999, 20 (05) :649-688
[5]   Be fit or be sick: Peroxisome proliferator-activated receptors are down the road [J].
Desvergne, B ;
Michalik, L ;
Wahli, W .
MOLECULAR ENDOCRINOLOGY, 2004, 18 (06) :1321-1332
[6]   Moving towards individualized medicine with pharmacogenomics [J].
Evans, WE ;
Relling, MV .
NATURE, 2004, 429 (6990) :464-468
[7]   Peroxisome proliferator-activated receptor-γ:: from adipogenesis to carcinogenesis [J].
Fajas, L ;
Debril, MB ;
Auwerx, J .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2001, 27 (01) :1-9
[8]  
Hisatake J, 2000, CANCER RES, V60, P5494
[9]  
James SY, 2003, CANCER RES, V63, P3531
[10]   Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARγ) signaling in prostate cancer [J].
Jiang, M ;
Shappell, SB ;
Hayward, SW .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (03) :513-527